A
PCVX icon

AlphaQuest’s Vaxcyte PCVX Stock Holding History

AlphaQuest’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,513
Closed -$485K – 1477
2025
Q4 		$485K Sell
10,513
-433
-4% -$19.4K 0.03% 849
2025
Q3 		$394K Buy
10,946
+6,517
+147% +$216K 0.03% 973
2025
Q2 		$144K Buy
4,429
+3,546
+402% +$116K 0.01% 1289
2025
Q1 		$33.3K Buy
+883
New +$70.6K ﹤0.01% 1620
2024
Q3 		– Sell
-926
Closed -$69.9K – 1969
2024
Q2 		$69.9K Buy
+926
New +$63K 0.01% 1018

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AlphaQuest's PCVX Position: Q1 2026 in Review

AlphaQuest sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 10,513 shares — an estimated $485K sold.

AlphaQuest first reported a position in PCVX in Q2 2024 and held it in 5 quarters. The position peaked at $485K in Q4 2025. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • AlphaQuest reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 10,513 Vaxcyte shares in Q1 2026, an estimated $485K.
  • AlphaQuest first reported a position in Vaxcyte in Q2 2024 and held it in 5 quarters.
  • AlphaQuest's Vaxcyte position peaked at $485K in Q4 2025.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.